The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1

Frontiers in Immunology

Volumn 9, Issue , 2018, Pages

  Anania, Jessica C ^a,b   Trist, Halina M ^a   Palmer, Catherine S ^a,b   Tan, Peck Szee ^a   Kouskousis, Betty P ^a,b   Chenoweth, Alicia M ^a,b   Kent, Stephen J ^b,c   Mackay, Graham A ^c   Hoi, Alberta ^d   Koelmeyer, Rachel ^d   Slade, Charlotte ^c,e,f   Bryant, Vanessa L ^c,e,f   Hodgkin, Philip D ^c,e   Aui, Pei Mun ^b,f   van Zelm, Menno C ^b,f   Wines, Bruce D ^a,b,g   Hogarth, P Mark ^a,b,g  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

common variable immunodeficiency; Fc receptors; immune complex; immunodeficiency; non human primates; systemic lupus erythematosus

Indexed keywords

BIOLOGICAL MARKER; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; IMMUNOGLOBULIN G; ISOPROTEIN; PROTEIN BINDING;

ANAPHYLAXIS; ANIMAL; DEGRANULATION; DISEASE PREDISPOSITION; DNA SEQUENCE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE LOCUS; GENETICS; HUMAN; IMMUNOLOGY; MACACA; MAST CELL; METABOLISM; MONONUCLEAR CELL; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANAPHYLAXIS; ANIMALS; BIOMARKERS; CELL DEGRANULATION; DISEASE SUSCEPTIBILITY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETIC LOCI; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MACACA; MAST CELLS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, IGG; SEQUENCE ANALYSIS, DNA;

EID: 85066492854     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01809     Document Type: Article

References (37)

1. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol (2002) 14(6):798–802.10.1016/S0952-7915(02)00409-012413532
2. Hogarth PM Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 11(4):311–31.10.1038/nrd290922460124
3. Hogarth PM Anania JC Wines BD. The FcgammaR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies. Curr Top Microbiol Immunol (2014) 382:321–52.10.1007/978-3-319-07911-0_15
4. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol (2005) 25(1):1–18.10.1007/s10875-005-0353-815742153
5. Ierino FL Powell MS McKenzie IF Hogarth PM. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the arthus reaction. J Exp Med (1993) 178(5):1617–28.10.1084/jem.178.5.16178228810
6. Tan Sardjono C Mottram PL van de Velde NC Powell MS Power D Slocombe RF et al. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum (2005) 52(10):3220–9.10.1002/art.2134416200626
7. Warmerdam PA van de Winkel JG Gosselin EJ Capel PJ. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med (1990) 172(1):19–25.10.1084/jem.172.1.192141627
8. Warmerdam PA Parren PW Vlug A Aarden LA van de Winkel JG Capel PJ. Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects. Immunobiology (1992) 185(2–4):175–82.10.1016/S0171-2985(11)80639-X
9. Vedeler CA Raknes G Myhr KM Nyland H. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome. Neurology (2000) 55(5):705–7.10.1212/WNL.55.5.705
10. Duits AJ Bootsma H Derksen RH Spronk PE Kater L Kallenberg CG et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 38(12):1832–6.10.1002/art.17803812178849356
11. Khor CC Davila S Breunis WB Lee YC Shimizu C Wright VJ et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet (2011) 43(12):1241–6.10.1038/ng.98122081228
12. Duan J Lou J Zhang Q Ke J Qi Y Shen N et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis. PLoS One (2014) 9(8):e103329.10.1371/journal.pone.010332925093412
13. Raknes G Skeie GO Gilhus NE Aadland S Vedeler C. FcgammaRIIA and FcgammaRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol (1998) 81(1–2):173–6.10.1016/S0165-5728(97)00174-49521619
14. van der Pol WL Jansen MD Kuks JB de Baets M Leppers-van de Straat FG Wokke JH et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. J Neuroimmunol (2003) 144(1–2):143–7.10.1016/j.jneuroim.2003.08.04314597109
15. Getahun A Cambier JC. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol Rev (2015) 268(1):66–73.10.1111/imr.1233626497513
16. Stuart SG Trounstine ML Vaux DJ Koch T Martens CL Mellman I et al. Isolation and expression of cDNA clones encoding a human receptor for IgG (Fc gamma RII). J Exp Med (1987) 166(6):1668–84.10.1084/jem.166.6.16682824655
17. de la Salle C Esposito-Farese ME Bieber T Moncuit J Morales M Wollenberg A et al. Release of soluble Fc gamma RII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Invest Dermatol (1992) 99(5):15S–7S.10.1111/1523-1747.ep126682501431201
18. Gachet C Astier A de la Salle H de la Salle C Fridman WH Cazenave JP et al. Release of Fc gamma RIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant Fc gamma RIIa2. Blood (1995) 85(3):698–704.7833473
19. van der Heijden J Geissler J van Mirre E van Deuren M van der Meer JW Salama A et al. A novel splice variant of FcgammaRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. J Allergy Clin Immunol (2013) 131(5):1408–16.e5.10.1016/j.jaci.2013.02.009
20. Brooks DG Qiu WQ Luster AD Ravetch JV. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med (1989) 170(4):1369–85.10.1084/jem.170.4.13692529342
21. Amigorena S Bonnerot C Drake JR Choquet D Hunziker W Guillet JG et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 256(5065):1808–12.10.1126/science.15354551535455
22. Aman MJ Tosello-Trampont AC Ravichandran K. Fc gamma RIIB1/SHIP-mediated inhibitory signaling in B cells involves lipid rafts. J Biol Chem (2001) 276(49):46371–8.10.1074/jbc.M10406920011571279
23. Reece JC Alcantara S Gooneratne S Jegaskanda S Amaresena T Fernandez CS et al. Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques. J Virol (2013) 87(8):4146–60.10.1128/JVI.02645-1223345519
24. Trist HM Tan PS Wines BD Ramsland PA Orlowski E Stubbs J et al. Polymorphisms and interspecies differences of the activating and inhibitory FcgammaRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol (2014) 192(2):792–803.10.4049/jimmunol.1301554
25. Hibbs ML Bonadonna L Scott BM McKenzie IF Hogarth PM. Molecular cloning of a human immunoglobulin G Fc receptor. Proc Natl Acad Sci U S A (1988) 85(7):2240–4.10.1073/pnas.85.7.22402965389
26. Ierino FL Hulett MD McKenzie IF Hogarth PM. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. J Immunol (1993) 150(5):1794–803.7679695
27. Bruhns P Iannascoli B England P Mancardi DA Fernandez N Jorieux S et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113(16):3716–25.10.1182/blood-2008-09-17975419018092
28. Bolte S Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc (2006) 224(Pt 3):213–32.10.1111/j.1365-2818.2006.01706.x17210054
29. Gustafsson MG. Nonlinear structured-illumination microscopy: wide-field fluorescence imaging with theoretically unlimited resolution. Proc Natl Acad Sci U S A (2005) 102(37):13081–6.10.1073/pnas.040687710216141335
30. Schwarzbaum S Nissim A Alkalay I Ghozi MC Schindler DG Bergman Y et al. Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions. Eur J Immunol (1989) 19(6):1015–23.10.1002/eji.18301906102473907
31. McDonnell JM Beavil AJ Mackay GA Jameson BA Korngold R Gould HJ et al. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat Struct Biol (1996) 3(5):419–26.10.1038/nsb0596-4198612071
32. Stuart SG Simister NE Clarkson SB Kacinski BM Shapiro M Mellman I. Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium. EMBO J (1989) 8(12):3657–66.2531080
33. Warmerdam PA van de Winkel JG Vlug A Westerdaal NA Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol (1991) 147(4):1338–43.1831223
34. Sunder-Plassmann R Lialios F Madsen M Koyasu S Reinherz EL. Functional analysis of immunoreceptor tyrosine-based activation motif (ITAM)-mediated signal transduction: the two YxxL segments within a single CD3zeta-ITAM are functionally distinct. Eur J Immunol (1997) 27(8):2001–9.10.1002/eji.18302708269295038
35. Kraft S Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol (2007) 7(5):365–78.10.1038/nri207217438574
36. Parren PW Warmerdam PA Boeije LC Arts J Westerdaal NA Vlug A et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 90(4):1537–46.10.1172/JCI1160221401085
37. Miettinen HM Matter K Hunziker W Rose JK Mellman I. Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J Cell Biol (1992) 116(4):875–88.10.1083/jcb.116.4.8751734021